相关实验视频

Updated: Jul 11, 2025

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment

Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment

Published on: December 27, 2024

新辅助化疗的疗效对于4型和大型3型胃癌不同

Wei Xu¹, Lingquan Wang¹, Wentao Liu¹

¹Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.

American journal of surgery

|November 7, 2023

概括

新辅助化疗 (NAC) 改善了中国3型胃癌 (GC) 大型患者的生存率. 然而,NAC没有显示4型GC的显著生存益处,表明需要量身定制的治疗策略.

科学领域:

胃肠病学胃肠病学
手术瘤学手术瘤学
医学瘤学医学瘤学

背景情况:

之前的研究,如JCOG0501,发现新辅助化疗 (NAC) 对4型和大型3型胃癌 (GC) 无效.
患有这些GC亚型的患者面临着不良预后,需要探索替代治疗策略.
在中国大型3型和4型GC患者中,非SPNAC疗程的疗效仍在研究中.

研究的目的:

评估NAC与非SP疗法对中国大型3型和4型GC患者的生存和术后结果的影响.
为了比较接受NAC之后手术和辅助化疗 (CSC组) 的患者和接受手术后辅助化疗 (SC组) 的患者之间的结果.

主要方法:

在2009年5月至2018年12月期间,对189名患有大型3型或4型GC的患者进行了D2胃切除术和辅助化疗 (AC) 的回顾性分析.
患者被分为两个组:CSC (NAC + 手术 + AC) 和SC (手术 + AC).
对每个GC亚型的CSC和SC组之间的生存和术后结果进行了比较.

主要成果:

对于大型3型GC,CSC组的5年整体存活率 (54.4%) 与SC组 (28.0%) (P=0.0008) 相比,CSC组的5年整体存活率显著更高.
对于4型GC,五年生存率在CSC组为15.8%,在SC组为24.8%,没有统计学上显著的差异 (P>0.05).

结论:

与非SP疗法结合的新辅助化疗 (NAC) 在中国人群中显示出对大型3型胃癌 (GC) 的生存益处.
在这项研究中,NAC没有为4型胃癌 (GC) 提供显著的生存优势.
大型3型和4型GC的治疗策略可能需要特定于亚型的方法.

关键词:

波尔曼 (Borrmann) 是一个人.胃癌胃癌是指胃癌.大型型号3型的大型型号新辅助化学疗法新辅助化学疗法第4种类型 4型

更多相关视频

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...